Related Experiment Video
Updated: Jul 19, 2026
06:01
Expression of Transgenes in Native Bladder Urothelium Using Adenovirus-Mediated Transduction
Published on: October 6, 2022
Transdermal drug delivery treatment for overactive bladder
Roger R Dmochowski1, Jonathan S Starkman, G Willy Davila
1Vanderbilt University Medical Center, Cleveland Clinic Florida, Weston, FL 33331, USA.
Summary
Transcutaneous oxybutynin offers an effective treatment for overactive bladder (OAB) and urinary incontinence. This method reduces side effects like dry mouth, improving patient adherence and symptom management.
Area of Science:
- Urology
- Pharmacology
Background:
- Overactive bladder (OAB) is frequently managed with oral anticholinergic drugs.
- Oral oxybutynin chloride is effective but often leads to discontinuation due to side effects like dry mouth.
- N-desethyloxybutynin (N-DEO) is implicated in these anticholinergic adverse events.
Purpose of the Study:
- To evaluate the efficacy and tolerability of transcutaneous oxybutynin delivery.
- To assess if transcutaneous delivery minimizes side effects associated with oral oxybutynin.
Main Methods:
- Transcutaneous delivery of oxybutynin was employed.
- Efficacy in controlling urinary urgency and incontinence was assessed.
- Incidence of side effects, particularly dry mouth, was monitored.
Main Results:
- Transcutaneous oxybutynin maintained therapeutic efficacy comparable to oral administration.
- Significant reduction in anticholinergic side effects, such as dry mouth, was observed.
- This delivery method avoids hepatic and gastrointestinal metabolism, reducing N-DEO formation.
Conclusions:
- Transcutaneous oxybutynin provides an effective and well-tolerated treatment option for OAB.
- Minimizing side effects enhances patient compliance and management of urge urinary incontinence.
- Novel drug delivery systems can improve therapeutic outcomes for bladder conditions.
Related Concept Videos
01:18Transdermal Drug Delivery Systems
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
01:22Drug Delivery: Miscellaneous Routes
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
01:21Intrauterine Drug Delivery Systems
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
01:27Drug Delivery Systems: Different Types
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...